Luminal B (ER-positive and/or PR-positive and HER2-positive) and HER2-enriched (ER-negative and PR-negative and HER2-positive) subtypes account for 4.6% and 10.3% of breast cancers, respectively. This evidence concerns the gene ESR1 and breast carcinoma.